Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Endocyte ( ECYT) is a biopharmaceutical company. The company is engaged in developing therapies for the treatment of cancer and inflammatory diseases.

Yesterday's Volume: 293,400

Average Volume: 151,305

Volume % Change: 55%

From a technical standpoint, this stock is very close to triggering a big breakout trade if it can manage to sustain a move and close above its 200-day moving average of $10.60 on volume that's close to or above its three-month average action of 151,305 shares. If we see that action, then traders should watch for ECYT to trend back toward $12 to $13.50.

To see more stocks rising on unusual volume, including ADA-ES ( ADES), Ebix ( EBIX) and Madison Square Garden ( MSG), check out the Stocks Rising On Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.


Follow Stockpickr on Twitter and become a fan on Facebook.
At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.

If you liked this article you might like

3 Industries and 3 Stocks Riding a 2012 M&A Boom

Idenix Falls Casualty to Gilead Hep C Hoopla

Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance

BioLineRx: Tuesday's Hot Hep C Drug Stock

Idenix Pharma Buyout Likely: Survey